Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route

Tuberculosis Clinical Trial

Official title:

A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intradermal Route in Healthy BCG-vaccinated Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01497769
• Other study ID #: TB026
• Status: Completed
• Phase: Phase 1
• First received: December 20, 2011
• Last updated: July 1, 2013
• Start date: September 2011
• Est. completion date: April 2013

Study information

• Verified date: July 2013
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This is a phase I trial to compare the safety and immunogenicity of candidate TB vaccine MVA85A administered by the aerosol inhaled route and the intradermal route in healthy BCG-vaccinated adult subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: April 2013
• Est. primary completion date: October 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Healthy adults aged 18-50 years

• Resident in or near Oxford for the duration of the trial period

• No relevant findings in medical history or on physical examination

• Confirmation of prior vaccination with BCG not less than 6 months prior to projected trial vaccination date (by visible BCG scar on examination or written documentation)

• Allow the Investigators to discuss the individual's medical history with their GP

• Use effective contraception for the duration of the trial period (females only)

• Refrain from blood donation during the trial

• Give written informed consent

• Allow the Investigator to register subject details with a confidential database to prevent concurrent entry into clinical trials

• Able and willing (in the Investigator's opinion) to comply with all the trial requirements

Exclusion Criteria:

• Any respiratory disease, including asthma

• Current smoker

• Clinically significant abnormality on screening chest x rays

• Clinically significant abnormality of pulmonary function tests

• Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy

• Current use of any medication taken through the nasal or inhaled route including cocaine or other recreational drugs

• Laboratory evidence at screening of latent M.tb infection as indicated by a positive ELISPOT response to ESAT6 or CFP10 antigens

• Clinical, radiological, or laboratory evidence of current active TB disease

• Previous vaccination with candidate vaccine MVA85A or candidate vaccine FP85A or any other recombinant MVA vaccine

• Clinically significant history of skin disorder, allergy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse

• History of serious psychiatric condition

• Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents

• History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, sedative drugs, or any local or general anaesthetic agents

• Any abnormality of screening blood or urine tests that is deemed to be clinically significant or that may compromise the safety of the subject in the trial

• Positive HBsAg, HCV or HIV antibodies

• Female currently lactating, confirmed pregnancy or intention to become pregnant during trial period

• Use of an investigational medicinal product or non-registered drug, live vaccine, or medical device other than the trial vaccine for 30 days prior to dosing with the trial vaccine, or planned use during the trial period

• Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date

• Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the subject at risk or may influence the result of the trial or may affect the subject's ability to participate in the trial

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Biological:
• Aerosol inhaled MVA85A
Aerosol inhaled MVA85A 1 x 10^7 pfu and intradermal saline placebo
• Intradermal MVA85A
Intradermal MVA85A 1 x 10^7 pfu and inhaled aerosol saline placebo

Locations

Country	Name	City	State
United Kingdom	Centre of Clinical Vaccinology and Tropical Medicine (CCVTM) Churchill Hospital	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of MVA85A vaccination by the aerosol inhaled route	To evaluate the safety in healthy BCG-vaccinated subjects of MVA85A vaccination by the aerosol inhaled route by actively and passively collecting data on adverse events	24 weeks following vaccination	Yes
Secondary	Immunogenicity of MVA85A vaccination by the aerosol inhaled route compared with the intradermal route	To evaluate the systemic and mucosal cellular immunogenicity in healthy BCG-vaccinated subjects of MVA85A vaccination by the aerosol inhaled route compared with the intradermal route by comparing laboratory markers of cell mediated immunity in blood and bronchoalveolar lavage samples	24 weeks following vaccination	No